The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Open accessAbstract
BACKGROUND Annualised figures show an up to 7-fold higher incidence of vascular thromboembolism (VTE) in patients with advanced pancreatic cancer (APC) compared to other common malignancies. Concurrent VTE has been shown to confer a worse overall prognosis in APC. METHODS One hundred and twenty three APC patients were randomised to receive either gemcitabine 1000 mg/m(2) or the same with weight-adjusted dalteparin (WAD) for 12 weeks. Primary end-point was the reduction of all-type VTE during the study period. NCT00462852, ISRCTN: 76464767. FINDINGS The incidence of all-type VTE during the WAD treatment period (<100 days from randomisation) was reduced from 23% to 3.4% (p = 0.002), with a risk ratio (RR)of 0.145, 95% confidence interval (CI) (0.035-0.612) and an 85% risk reduction. All-type VTE throughout the whole follow-up period was reduced from 28% to 12% (p = 0.039), RR = 0.419, 95% CI (0.187-0.935) and a 58% risk reduction. Lethal VTE <100 days was seen only in the control arm, 8.3% compared to 0% (p = 0.057), RR = 0.092, 95% CI (0.005-1.635). INTERPRETATION Weight adjusted dalteparin used as primary prophylaxis for 12 weeks is safe and produces a highly significant reduction of all-type VTE during the prophylaxis period. The benefit is maintained after dalteparin withdrawal although decreases with time.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Malignancies, prothrombotic mutations, and the risk of venous thrombosis
Blom, J. W. (2005) · JAMA · doi:10.1001/jama.293.6.715 · Cited by 1,949
Cited by
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma
Grossberg, A. J., Chu, L. C., Deig, C. R., Fishman, E. K., Hwang, W. L., Maitra, A., Marks, D. L., Mehta, A., Nabavizadeh, N., Simeone, D. M., et al. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21626 · Cited by 489
Farge, D., Frere, C., Connors, J. M., Khorana, A. A., Kakkar, A., Ay, C., Muñoz, A., Brenner, B., Prata, P. H., Brilhante, D., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00160-7 · Cited by 486
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Di Nisio, M., Porreca, E., Ferrante, N., Otten, H.-M., Cuccurullo, F., & Rutjes, A. W. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008500.pub2 · Cited by 264
Current and Emerging Therapies in Metastatic Pancreatic Cancer
Manji, G. A., Olive, K. P., Saenger, Y. M., & Oberstein, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2319 · Cited by 145
Young, A., Chapman, O., Connor, C., Poole, C., Rose, P., & Kakkar, A. K. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.106 · Cited by 150
Infante, J. R., Korn, R. L., Rosen, L. S., LoRusso, P., Dychter, S. S., Zhu, J., Maneval, D. C., Jiang, P., Shepard, H. M., Frost, G., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.327 · Cited by 83
Metadata
- Authors
- Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., Sgouros, J., Gardiner, E., Wedgwood, K., Ettelaie, C., & Bozas, G.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2012-06
- Volume
- 48
- Issue
- 9
- Pages
- 1283-1292
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W1973509710
- Cited by
- 316
- References
- 3
- FWCI
- 18.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
